Cipla Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Cipla Ltd. on BSE

Search Inside the pdf :

Cipla Ltd.

11 Apr 2025

1463.05

3.35%

Company Update

Cipla Ltd - 500087 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure …

BSE India

Company has received final approval from USFDA for ANDA submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial (''Protein-bound Paclitaxel'') on 10th April, 2025

pdf

Cipla Ltd.

07 Apr 2025

1463.05

3.35%

Board Meeting

Cipla Ltd - 500087 - Board Meeting Intimation for Quarter And Year Ended 31St March 2025 …

BSE India

Cipla Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2025 ,inter alia, to consider and approve 1. the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended 31st March 2025. 2. Recommend final dividend for the year ended 31st March 2025, if any. In terms of the Company's Code of Conduct for Prevention of Insider Trading, the 'Trading Window' for dealing in the securities of the Company is closed from Tuesday, 1st April, 2025 till Thursday, 15th May, 2025 (both days inclusive) for the purpose of financial results.

pdf

Cipla Ltd.

19 Mar 2025

1463.05

3.35%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

In compliance with the provisions of Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 19th March, 2025 has allotted 2,179 fully paid up equity shares of INR 2 each pursuant to exercise of employee stock options/stock appreciation rights under the Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company.

pdf

Cipla Ltd.

20 Feb 2025

1463.05

3.35%

Company Update

CIPLA LTD. - 500087 - USFDA Inspection At Analytical Testing Facility Of Sitec In Mahape, Navi …

BSE India

USFDA inspection at analytical testing facility of Sitec Labs Limited in Mahape, Navi Mumbai, India

pdf

Cipla Ltd.

20 Feb 2025

1463.05

3.35%

Company Update

CIPLA LTD. - 500087 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure …

BSE India

Company has received final approval from USFDA for NDA submitted for Nilotinib Capsules 50, 150 and 200 mg on 19th February, 2025

pdf

Cipla Ltd.

18 Feb 2025

1463.05

3.35%

Company Update

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Updates on Acquisition

BSE India

Update on investment in Cipla Medpro South Africa Proprietary Limited

pdf

Cipla Ltd.

18 Feb 2025

1463.05

3.35%

Investor Presentation

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

In furtherance to our intimation dated 10th February, 2025, we are hereby enclosing investor presentation to be made at the Kotak Conference.

pdf

Cipla Ltd.

13 Feb 2025

1463.05

3.35%

Company Update

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

In compliance with regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that the Operations and Administration Committee of the Company on 13th February, 2025 has allotted 901 equity shares of INR 2/- each pursuant to exercise of Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company

pdf

Cipla Ltd.

10 Feb 2025

1463.05

3.35%

Company Update

CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein mention the schedule of Analyst / Institutional Investor Meeting with the Company

pdf